Life sciences supply chains are entering a period of reassessment in an effort to reduce shortages. After years of prioritizing efficiency and global reach, manufacturers are taking a closer look at how production location influences reliability, quality oversight, and long‑term access to critical therapies.
Recent disruptions have accelerated this shift, prompting renewed attention on where and how essential drugs and medical products are made. As organizations evaluate options for strengthening supply continuity, onshoring (also called reshoring)has moved from a policy discussion into an operational consideration.
By bringing selected manufacturing and supply functions closer to end markets, life sciences companies are exploring ways to reduce exposure to supply chain shortages while improving coordination across manufacturing, quality, and regulatory operations.
READ NEXT: 5 Reasons U.S Companies are Reshoring in Certain Industries
Factors Causing Supply Chain Shortages
Supply chain shortages in life sciences rarely stem from a single failure. Instead, these shortages are often the result of overlapping structural, economic, and operational conditions that limit flexibility across the drug supply chain.
Manufacturing Quality Issues
Manufacturing and quality problems remain one of the most common contributors to drug shortages. Shortages can frequently arise from compliance issues, production interruptions, and quality failures that require facilities to slow or halt manufacturing while corrective actions are implemented.
The Government Accountability Office (GAO) has similarly found that quality lapses, particularly in facilities producing complex products such as sterile injectables, are closely associated with prolonged shortages.
Limited Manufacturing Redundancy
Many drugs, especially generics, are produced by a small number of manufacturers or even a single facility. When one site experiences a disruption, alternative capacity is often unavailable or slow to activate.
Policy analyses from the Office of the Assistant Secretary for Planning and Evaluation (ASPE) identify limited redundancy as a key structural weakness that makes supply chains slow to recover from disruptions.
Economic Pressures in Generic Drug Markets
Pricing dynamics play a significant role in shaping supply resilience. According to the GAO’s Drug Shortages Survey, low prices for generic drugs can reduce incentives for manufacturers to invest in modernization, quality improvements, or backup capacity.
Over time, these pressures increase the likelihood that clinically essential products are produced under constrained and fragile conditions.
Concentration of Global Manufacturing
Geographic concentration heightens exposure to regional disruptions. According to the FDA, over half of brand‑name drugs and nearly 70% of generic drugs distributed in the U.S. are manufactured overseas, while only 9% of API manufacturers are located domestically.
When geopolitical events, natural disasters, or logistics disruptions occur, supply recovery can take months rather than weeks.
Demand Fluctuations and Capacity Constraints
Unexpected increases in demand can strain already tight manufacturing capacity. When combined with limited production flexibility, demand spikes can exacerbate existing vulnerabilities and push products into shortage.
Supply Chain Visibility Gaps
Limited transparency across suppliers and subcontractors can delay the detection of emerging risks. According to the USP Annual Drug Shortages Report, limited insight into upstream manufacturing conditions makes it difficult for purchasers and regulators to anticipate disruptions before they affect availability.
How Onshoring Addresses Supply Chain Shortages
Onshoring does not eliminate every supply risk, but it directly addresses several of the structural conditions that contribute to recurring supply chain shortages. Domestic manufacturing can improve visibility, responsiveness, and long‑term supply stability for critical medicines—which is why there’s been both a federal and organizational push toward onshoring.
Improved Oversight and Faster Issue Resolution
Domestic manufacturing allows closer coordination between manufacturers, quality teams, and regulators. Offshoring, on the other hand, can complicate oversight and slow response times when quality or production issues arise.
U.S.‑based facilities enable more frequent engagement and earlier intervention, reducing the likelihood that localized issues escalate into national shortages.
Reduced Exposure to Geographic Disruptions
Onshoring shortens supply lines and lowers dependence on a limited number of overseas manufacturing regions. Expanding domestic capacity helps distribute risk and improves recovery timelines when disruptions occur.
Greater Manufacturing Redundancy
Domestic production makes it more feasible to build redundant capacity for high‑risk products. The Administration for Strategic Preparedness and Response (ASPR) emphasizes that redundancy, especially for essential and generic medicines, is a key factor in preventing shortages and accelerating recovery after disruptions.
Onshoring supports this goal by lowering barriers to adding secondary production lines and alternative sites within the same regulatory framework.
Stronger Quality System Alignment
Quality failures are a frequent trigger for drug shortages. Onshoring supports tighter alignment between manufacturing operations and quality management systems, making it easier to maintain consistent standards and address deviations quickly.
FDA initiatives designed to encourage domestic manufacturing, such as early engagement during facility development, are intended to support higher levels of quality system maturity and more reliable output over time.
More Predictable Regulatory Pathways
Regulatory predictability plays a role in supply stability, which is why there have been recent federal efforts to streamline regulatory review for domestic efforts. The Executive Order aimed at accelerating the establishment of U.S. manufacturing sites seeks to reduce uncertainty during facility development and scale‑up, helping manufacturers bring capacity online more efficiently.
Enhanced Supply Chain Transparency
Domestic operations improve transparency across suppliers, subcontractors, and production sites. The office of the Assistant Secretary for Planning and Evaluation (ASPE) highlight transparency as a prerequisite for early risk detection and shortage prevention.
Onshoring supports clearer insight into upstream inputs and production conditions, enabling earlier mitigation when vulnerabilities emerge.
Building Resilience Requires More Than Facilities
Supply chain shortages will persist as long as production remains concentrated, quality systems remain strained, and execution capacity remains thin. Onshoring offers a credible path toward greater stability.
Insight Global supports life sciences organizations by providing functional expertise across quality, validation, engineering, and regulatory operations. By aligning workforce strategy with operational goals, companies can turn onshoring into a durable supply advantage rather than a temporary response.
Contact us to get started.
